The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 dose escalation study of MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors.
 
Sekwon Jang
Consulting or Advisory Role - Bristol-Myers Squibb; EMD Serono; Genentech; Novartis; Sanofi; Sun Biopharma
 
John D. Powderly
Employment - BioCytics; Carolina BioOncology Institute
Leadership - BioCytics; Carolina BioOncology Institute
Stock and Other Ownership Interests - BioCytics; Bluebird Bio; Carolina BioOncology Institute; Juno Therapeutics; Kite, a Gilead company; Lion Biotechnologies; ZIOPHARM Oncology
Consulting or Advisory Role - Abbvie; AstraZeneca/MedImmune; Bristol-Myers Squibb; Curis; Genentech/Roche; TERUMO; TopAlliance BioSciences Inc
Speakers' Bureau - Bristol-Myers Squibb; Dendreon; Genentech/Roche; Merck
Research Funding - Abbvie; Alkermes; Apros Therapeutics; Arcus Biosciences; AstraZeneca/MedImmune; Atreca (Inst); BioBank Online (Inst); Bristol-Myers Squibb; Calico; CEM Corporation (Inst); Corvus Pharmaceuticals; Curis; EMD Serono; Engineered BioPharmaceuticals (Inst); FLX Bio; Genentech/Roche; Incyte; Jounce Therapeutics; Lilly/ImClone; Macrogenics; Merck (Inst); MT Group (Inst); Precision for Medicine (Inst); Replimune (Inst); Seagen; Sequenom (Inst); STEMCELL Technologies (Inst); Tempest Therapeutics; Therapeutic BrainPower LLC (Inst); Top Alliance BioScience
Patents, Royalties, Other Intellectual Property - BioCytics is developing intellectual property for cellular immunotherapy
Other Relationship - Ongoing discussions with potential future biopharma and biotech for Human Applications Lab sponsored projects
 
Alexander I. Spira
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Gritstone Bio; incyte; Jazz Pharmaceuticals; Merck (Inst); Mirati Therapeutics; Novartis
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Amgen (Inst); Arch Therapeutics (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Mirati Therapeutics (Inst); Newlink Genetics (Inst); Novartis (Inst); Plexxikon (Inst); Roche (Inst); Rubius Therapeutics (Inst); Takeda (Inst); Trovagene (Inst)
 
Ouiam Bakkacha
Employment - MacroGenics
Stock and Other Ownership Interests - MacroGenics
 
Deryk Loo
Employment - MacroGenics; MacroGenics (I)
Stock and Other Ownership Interests - MacroGenics; MacroGenics (I)
 
Gerry C. Bohac
Employment - Macrogenics
Stock and Other Ownership Interests - Amgen; Amgen; Macrogenics; Macrogenics; Macrogenics
 
Manish Sharma
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Alexion Pharmaceuticals; Amgen; Biogen; Bristol-Myers Squibb; Lilly; Medtronic; Merck; Pfizer; Regeneron
Research Funding - Alexo Therapeutics (Inst); Alpine Immune Sciences (Inst); Arrys Therapeutics (Inst); Ascentage Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bolt Biotherapeutics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Compugen (Inst); Constellation Pharmaceuticals (Inst); Coordination Pharmaceuticals (Inst); CytomX Therapeutics (Inst); eFFECTOR Therapeutics (Inst); Epizyme (Inst); Exelixis (Inst); Forty Seven (Inst); Genmab (Inst); GlaxoSmithKline/Tesaro (Inst); Helsinn Therapeutics (Inst); Ikena Oncology (Inst); InhibRx (Inst); Innovent Biologics (Inst); Jounce Therapeutics (Inst); KLUS Pharma (Inst); Loxo (Inst); Macrogenics (Inst); Merck (Inst); Mersana (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); PureTech (Inst); Regeneron (Inst); Sapience Therapeutics (Inst); Seagen (Inst); Shattuck Labs (Inst); Symphogen (Inst); Syros Pharmaceuticals (Inst); Tempest Therapeutics (Inst); Treadwell Therapeutics (Inst)